Beikang Medical's overseas product collection

[shapanwwuom]

Recently, Beikang Medical, the first listed company in assisted reproductive IVD focusing on the entire industry chain of reproductive health, released its unaudited operating report for 2024, achieving annual revenue of approximately RMB 300 million, a year-on-year surge of more than 40%, indicating that its international full-industry chain strategic deployment has begun to bear fruit and is expected to grow into the most innovative company in the global assisted reproductive field.

Revenue grew by more than 40% against the trend, achieving a closed loop of the entire industry chain in the reproductive field

Through years of R&D investment in the field of assisted reproduction, Beikang Medical has led a three-in-one innovation model centered on "original innovation + global mergers and acquisitions + digital intelligence" and has built embryo laboratories, genetic laboratories, andrology laboratories and low-temperature storage laboratory solutions with british student data internationally leading levels around the world. At the same time, the company combines the clinical application of artificial intelligence in assisted reproduction and connects all laboratory hardware equipment to the iARMS electronic medical record system to provide reproductive centers with overall upgrades and solutions for "smart" reproductive centers.

In 2024, Beikang Medical will obtain medical device registration certificates for a number of major equipment and complete the ramp-up period from innovative products to registered products. This will further enhance the company's competitiveness, expand the company's product pipeline, optimize the company's sales costs, and significantly enhance Beikang Medical's brand influence and industry status in the global assisted reproductive field.

DA5000 high-throughput gene sequencer approved

In 2024, Beikang Medical's independently developed DA5000 high-throughput gene sequencer was approved for the national Class III medical device registration certificate. This milestone hardware upgrade has greatly consolidated the company's reproductive genetic technology R&D capabilities and platform advantages. Combined with the company's DA500 device, which has already obtained a registration certificate, it has formed a high-low matching sequencing platform that can provide complete solutions for clinical institutions of different sizes. The certification of DA5000 has significantly enhanced the overall competitiveness of the company's products.